Novo Nordisk's Pill Price War Intensifies as AI Strategy Unfolds
Published on 04/17/2026 at 08:11 | Redaktion boerse-global.de
Novo Nordisk's stock, trading around €34.70, finds itself caught in a stark contradiction. While its new oral weight-loss drug is seeing a rapid uptake in the United States, its share price has plummeted by more than 50% since last summer. This disconnect highlights the intense pressure the Danish pharmaceutical giant faces from a brutal price war and shifting market dynamics, even as it deploys aggressive commercial tactics and a bold technological partnership.
The competitive landscape shifted decisively on April 1, 2026, with the FDA approval of Eli Lilly's rival oral drug, Foundayo. This set the stage for a direct pricing duel. Lilly initially set a monthly price of up to $399, prompting Novo to counter with an introductory offer of $149 for its Wegovy pill, capping at $299. In response, Lilly retreated to a $299 price point, but only for patients who continuously renew their prescription. Novo’s own introductory price for the 4mg Wegovy tablet expired on April 15, rising from $149 to $199 per month, with its highest maintenance doses costing $299.
Looking ahead, Novo has signaled even more dramatic price action for 2027, announcing plans to slash the list price for its three main products to approximately $675 monthly—a move that would effectively halve current prices. This aggressive pricing strategy is a direct response to the severe margin pressure in the critical North American market, driven by Medicaid cuts and new pricing agreements. Company management now forecasts a currency-adjusted decline in both sales and operating profit for 2026, expecting a drop of between 5% and 13%.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Beyond pricing, Novo is fighting on clinical grounds. At a recent medical conference, it presented data from the ORION study showing its Wegovy tablet achieved a 13.6% weight reduction over 64 weeks, outperforming the 11.2% loss seen with the competitor compound orforglipron over 72 weeks. The company also emphasizes the long-term safety profile established by its injectable semaglutid. However, the oral Wegovy has a practical drawback: it must be taken at least 30 minutes before the first meal of the day, a restriction not shared by orforglipron.
Commercial execution appears strong initially. Weekly prescriptions for the oral Wegovy in the U.S. are reportedly about three times higher than those for tirzepatide at its launch. The pill is now available in over 70,000 pharmacies, though most patients are currently paying out of pocket. To lock in these new users—the majority of whom are first-time GLP-1 patients—Novo has introduced a subscription model. Patients committing to three, six, or twelve months can save up to $1,200 annually on the injection or $600 on the pill.
Simultaneously, the company is making a long-term technological bet. A new strategic partnership with OpenAI aims to significantly accelerate drug discovery and development, with full integration of AI systems into research and production targeted by the end of 2026. In the nearer term, management is supporting the share price through a buyback program, channeling up to 3.8 billion Danish kroner into repurchasing B-shares by early May as part of a larger 15-billion-kroner initiative.
The market’s skepticism is palpable. The stock’s Relative Strength Index (RSI) sits at a deeply oversold 25, reflecting persistent selling pressure. With shares down roughly 22% since the start of the year, investor focus is fixed on a single metric: how quickly Eli Lilly’s Foundayo gains prescription traction in the coming weeks. For Novo Nordisk, the battle for market share in the oral GLP-1 arena has become inextricably linked to the fate of its stock.
Ad
Novo Nordisk Stock: New Analysis - 17 April
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
